摘要
目的探讨达格列净联合二甲双胍治疗冠心病合并2型糖尿病患者的疗效和对同型半胱氨酸(Hcy)、C反应蛋白(CRP)和尿酸(UA)的影响。方法方便选取该院2020年2月—2021年2月收治的76例冠心病合并2型糖尿病患者,随机分为对照组和观察组,各38例,对照组给予二甲双胍治疗,观察组则在对照组基础上给予达格列净治疗,两组均治疗8周后,比较两组的临床疗效,治疗前后空腹血糖(FPG)、糖化血红蛋白(HbA1c)和体质量指数(BMI),同时检测Hcy、CRP和UA水平变化。结果观察组患者的临床总有效率94.74%高于对照组76.32%,差异有统计学意义(χ^(2)=5.208,P<0.05)。与治疗前相比,治疗后两组FPG、HbA1c和BMI均下降,且观察组FPG(5.82±0.73)mmol/L、HbA1c(6.31±0.79)%、BMI(25.18±0.97)kg/m^(2)低于对照组,差异有统计学意义(t=6.380、3.705、6.383,P<0.05)。与治疗前相比,两组Hcy、CRP、UA均有所降低,差异统计学意义(P<0.05),观察组Hcy、CRP、UA水平均低于对照组,差异统计学意义(P<0.05)。结论达格列净联合二甲双胍可有效控制冠心病合并2型糖尿病患者血糖水平,同时可调控多种危险因素,值得临床上推广应用。
Objective To investigate the efficacy of dapagliflozin combined with metformin in the treatment of patients with coronary heart disease and type 2 diabetes and the effect on homocysteine(Hcy),C-reactive protein(CRP)and uric acid(UA).Methods A total of 76 patients with coronary heart disease and type 2 diabetes who were admitted to the hospital from February 2020 to February 2021 were conveniently selected and randomly divided into a control group and an observation group,with 38 cases in each.The control group was treated with metformin,and the observation group was in the control group Dapagliflozin was given on the basis of treatment.After 8 weeks of treatment in both groups,the clinical efficacy of the two groups was compared,fasting blood glucose(FPG),glycosylated hemoglobin(HbA1c)and body mass index(BMI)before and after treatment,and the changes in Hcy,CRP and UA levels were also detected.Results The total clinical effective rate of the observation group was 94.74%higher than that of the control group 76.32%.The difference was statistically significant(χ^(2)=5.208,P<0.05).Compared with before treatment,FPG,HbA1c and BMI of the two groups decreased after treatment,and the observation group had FPG(5.82±0.73)mmol/L,HbA1c(6.31±0.79)%,and BMI(25.18±0.97)kg/m^(2)lower than control group,the difference was statistically significant(t=6.380,3.705,6.383,P<0.05).Compared with before treatment,Hcy,CRP,UA of the two groups were reduced,the difference was statistically significant(P<0.05),while the observation group Hcy,CRP The UA level was lower than the control group,the difference was statistically significant(P<0.05).Conclusion Dapagliflozin combined with metformin can effectively control the blood glucose level of patients with coronary heart disease and type 2 diabetes,and can also regulate a variety of risk factors.It is worthy of clinical application.
作者
曾宪辉
麦瑞林
周衍国
黄敏旋
杨志强
谢锦智
ZENG Xianhui;MAI Ruilin;ZHOU Yanguo;HUANG Minxuan;YANG Zhiqiang;XIE Jinzhi(Second Department of Internal Medicine,Dongguan Qishi Hospital,Dongguan,Guangdong Province,523500 China)
出处
《中外医疗》
2021年第21期116-119,共4页
China & Foreign Medical Treatment
